Bristol-myers Squibb Compnay

Donna Dambach

Gregory Opiteck

Leah Ann Garulacan

Frederic Moulin

Stephen K Durham

Stanley Hefta

Jun-Hsiang Lin

Ji Gao

Stephen M Storm

The present invention relates to biomarker polypeptides, polynucleotides, and antibodies that have utility in predicting in vitro and/or in vivo hepatotoxicity of various drugs, compounds, or other therapeutic agents (i.e., test substances). Also related are screens, kits, microarrays, and cell culture systems that employ the polypeptides, polynucleotides, and/or antibodies of the invention. The reagents and methods of the invention are useful for predicting hepatotoxic effects resulting from treatment with one or more test substances, and can be utilized before, after, or concurrently with pre-clinical, clinical, and/or post-clinical testing. In this way, the reagents and methods of the invention can be used to identify test substances or combinations of test substances that cause hepatic injury, including idiosyncratic hepatotoxicity, and thereby prevent medical complications (e.g., liver failure) resulting from such injury.

Identification of biomarkers for liver toxicity

Growing community of inventors

Wyncote, PA, United States of America

Donna Dambach